Taysha Gene Therapies Inc.

Clinical-stage gene therapy company focused on AAV9-based one-time treatments for severe monogenic CNS diseases. Lead program TSHA-102 for Rett syndrome uses proprietary miRARE auto-regulatory technology with FDA Breakthrough Therapy Designation; pivotal dosing completion expected Q2 2026.